Celgene to acquire Abraxis Bioscience for $2.9 billion up front
This article was originally published in Scrip
Executive Summary
Celgene is to acquire Abraxis Bioscience for $2.9 billion up front in a deal aimed at boosting its oncology presenceby immediate entry into solid tumours, building on Celgene's blood cancers business.
You may also be interested in...
Celgene Settlement With Actavis Allows Abraxane Generics In 2022
Celgene settles Abraxane patent litigation and inter partes review with Teva's Actavis, allowing a generic to enter the market on March 31, 2022 – about four years before the drug's key patents expire.
Celgene's Partnered Pipeline Delivers Successes And Setbacks
Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.